Enterprise Europe Network

Frailty diagnosis through biomarkers

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20210204003
Published
12/02/2021
Last update
12/02/2021
Expiration date
13/02/2022

Keywords

Partner keyword: 
Clinical Research, Trials
Cytology, Cancerology, Oncology
Medical Research
Medical Technology / Biomedical Engineering
Diagnostic services
Orthopaedics
Anatomy, Pathology, Immunology, Physiology
Hospital activities
Specialist medical practice activities
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish (Basque) scientific foundation specialized in R&D and innovation management for the healthcare system seeks a company to license an in vitro (biomarker-based) method for diagnosing and/or predicting whether an individual is or is likely to become frail.

Description

Description: 

Frailty is defined as a geriatric condition or syndrome characterised by a decline in functional reserve and adaptive capacity in older people. This decline leads to a general worsening in health that tends to progress towards dependency. Unlike dependency, frailty is reversible and there is substantial evidence of the effectiveness of interventions based on muscle strengthening through exercise, improving diet, and reducing polypharmacy, among other approaches. Frailty is independently associated with an elevated risk of death, loss of independence, falls and fractures, hospitalisations and reductions in health-related quality of life.
It is very important to identify frail older individuals as it makes it possible, through personalised interventions tailored to the needs of individuals and their families, to slow the natural progression of frailty towards dependency.
This invention provides a new method for the diagnosis of frail individuals and distinguishing them from more robust or dependent individuals based on measurements of the level of protein expression and/or transcription of a range of molecular markers identified by complete transcriptome analysis.

The organization is offering a license agreement to experienced companies from the health sector interested in acquiring this technology. Although it is not compulsory, it would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out.

Advantages & innovations

Cooperation plus value: 
The innovative diagnosis method is simple, rapid and reliable. It is important to note that it is a non-invasive method. Thus, no break in the skin is created and there is no contact with the mucosa, or skin break, or internal body cavity beyond a natural or artificial body orifice. Moreover, this method not only allows an early diagnosis but it also predicts the development of it. This way, measures may be implemented to slow the illness progression towards a dependency state.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The Spanish (Basque) organization is offering a license agreement to experienced companies in preclinical and clinical development of medical devices and diagnostic kits interested in acquiring this technology. Moreover, this license offer seeks both options: On the one side, companies willing to commercialise, but also companies interested in enhancing the invention. It would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out. Nevertheless, this is not compulsory.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,SME 51-250,>500